Real-time PCR-based method for the rapid detection of extended RAS mutations using bridged nucleic acids in colorectal cancer
- 1 February 2019
- journal article
- research article
- Published by Elsevier BV in Clinica Chimica Acta; International Journal of Clinical Chemistry
- Vol. 489, 164-168
- https://doi.org/10.1016/j.cca.2017.10.026
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancerEuropean Journal Of Cancer, 2015
- Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter StudyEBioMedicine, 2015
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2014
- PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal CancerJournal of Clinical Oncology, 2014
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal CancerThe New England Journal of Medicine, 2013
- Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal CancerClinical Cancer Research, 2013
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation StatusJournal of Clinical Oncology, 2011
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerThe New England Journal of Medicine, 2008
- Ras oncogenes: split personalitiesNature Reviews Molecular Cell Biology, 2008
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008